AKT1 and breast carcinoma: In HER2-amplified breast cancer models, both RICTOR gene knockout and nanoparticle-based delivery of Rictor RNAi—an RNA-mediated strategy to block expression of a specific gene—blocked mTORC2/Akt-dependent tumor cell survival and metastasis in vivo (24) and improved tumor response to the HER2 kinase inhibitor lapatinib (25).